Abellas-Sequeiros RA, et al. - Researchers focused on the early and mid-term clinical outcomes in patients who had angioplasty with the Essential paclitaxel-coated balloon (PCB) for treating de-novo lesions in small vessels (reference diameter < 2.5 mm). These patients underwent the procedure between October 2015 and June 2016 in 2 centers. Angiographic success was achieved in 97.2% of cases. Nine (12.7%) cases needed bail-out stenting. At the 12-month follow-up, the estimated incidence of target lesion failure (TLF) was 4.2%, with a target lesion revascularization rate of 4.2%. As estimated, target vessel failure and global major adverse cardiac events (MACE) rates were 4.2 and 9.9%, respectively. Based on the findings, they concluded that the Essential PCB affords a safe option for treating de-novo coronary lesions in small vessels, with low TLF and MACE rates reported in this study.